General Information of Drug (ID: DMS6ZA0)

Drug Name
BTD-001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Narcolepsy 7A20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMS6ZA0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting GABA(A) receptor (GABAR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PH94B NS DMDC7OH Social anxiety disorder 6B04 Phase 3 [2]
OV101 DMA6LR3 Angelman syndrome LD90.0 Phase 3 [3]
Padsevonil DMRZ1F2 Epilepsy 8A60-8A68 Phase 2/3 [4]
SAGE-324 DM5NC39 Essential tremor or related tremors 8A04.1 Phase 2 [5]
Evt201 DM8QXEY Sleep-wake disorder 7A00-7B2Z Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor (GABAR) TTCI43M NOUNIPROTAC Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.
4 Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
5 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
6 The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.